Format

Send to

Choose Destination
See comment in PubMed Commons below
Leuk Res. 2008 Dec;32(12):1837-41. doi: 10.1016/j.leukres.2008.04.005. Epub 2008 May 19.

Clinicopathologic features and treatment outcome of primary breast diffuse large B-cell lymphoma.

Author information

1
Department of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan. nniitsu@saitama-med.ac.jp

Abstract

We studied the clinicopathologic features and treatment outcome of patients with breast diffuse large B-cell lymphoma. As to the cellular immunophenotype, CD5 was detected in two patients, CD10 in 4, BCL2 in 20, BCL6 in 11, and MUM-1 in 17. The 5-year progression-free survival was 77% and the 5-year overall survival was 87%. Patients with the germinal center B-cell (GCB) type had a significantly better prognosis than those with the non-GCB type. The combination of anthracycline-containing chemotherapy and/or involved-field radiotherapy produced a relatively good prognosis. However, it is a heterogeneous disease with regard to histological type and pathological state.

PMID:
18490056
DOI:
10.1016/j.leukres.2008.04.005
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center